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Abstract 
 
Patient Survival following Pancreas After Kidney transplantation (PAK) has been 
reported to be inferior to patient survival following Simultaneous Pancreas and Kidney 
transplantation (SPK). This analysis examines national data to further explore allograft 
(kidney and pancreas) and patient survival after PAK. Kaplan-Meier and Cox 
proportional Hazard models were used to analyze OPTN data from 1995-2010. The 
analysis compared PAK and SPK candidates and recipients. Kaplan-Meier analysis 
demonstrated that PAK following either a living or deceased donor kidney transplant is 
associated with increased kidney graft survival compared to Type 1 diabetic recipients 
who only received a kidney. The best kidney allograft survival was for living donor 
kidney followed by PAK. Living donor kidney was associated with increased pancreas 
allograft survival compared to deceased donor kidney. PAK transplant recipients who 
receive both organs have a survival advantage compared to uremic candidates who 
receive neither (SPK waitlist). Compared to uremic diabetic waitlist patients, SPK and 
PAK recipients showed similar overall patient survival. Successful PAK offers a survival 
advantage compared to receiving neither a kidney nor a pancreas transplant.  These data 
also suggest that receiving a pancreas (after kidney) transplant may have a protective 
effect on the kidney allograft.  
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Introduction: 
 
Beginning in 2004, there has been a profound decline in the number of pancreas 
transplants performed in the United States (1, 2). Although several factors may  
contribute, there is a perception in the pancreas transplant community that this decline, 
particularly pancreas after kidney transplantation (PAK), occurred immediately following 
publication of a study funded by the National Institutes of Health in the Journal of the 
American Medical Association (JAMA) in 2003(3). This study was a retrospective 
observational study performed as a query to the Organ Procurement and Transplantation 
Network (OPTN) database comparing survival rates at 1 and 4 years post-transplant and 
the relative risk of death between patients on the waiting list for a subsequent pancreas 
following their kidney and pancreas transplant recipients. In that study, the authors 
concluded that patients receiving solitary pancreas transplants, including PAK, had an 
increased mortality risk compared to those remaining on the waiting list and receiving 
conventional medical therapy. Two subsequent rebuttal studies have been published from 
the International Pancreas Transplantation Registry (IPTR) employing a similar study 
design and using the same database(4, 5). However, these studies uniquely included 
supplemental data from the IPTR and accounted for recipients listed more than once, 
recipients that were not re-categorized after isolated renal transplantation and recipients 
that were inappropriately excluded. Notably, these studies came to a contradictory 
conclusion compared to the JAMA report indicating that PAK transplanted recipients did 
not have increased mortality compared to those waiting for a PAK. Despite these 
additional analyses and published studies, there remains reticence among physicians to 
offer PAK transplants due to the possible negative impacts on kidney function and patient 
survival. Given the discrepancy of results in the literature, further critical analyses are 
necessary to correct a possible misapprehension and achieve a more comprehensive view 
of the overall benefits and risks of PAK transplants.  
Pancreas transplantation is frequently considered only a life-enhancing rather than 
a life-saving procedure. However, abundant evidence indicates that, similar to kidney 
transplantation, successful pancreas transplantation is clearly life-extending. For 
example, the University of Wisconsin published their experience with one thousand 
kidney-pancreas transplantations with 22 year follow-up(6). In this retrospective analysis, 
patient survival following transplantation of both a kidney and a pancreas was 
dramatically superior to all other options for type 1 diabetic uremic patients, particularly 
deceased donor renal transplantation alone and dialysis options. Although not evident for 
the first 4 to 5 years (beyond the 4 year interval of the prior mentioned publications), with 
the extended follow-up achieved in this particular study, the long-term patient survival 
following simultaneous pancreas and kidney transplantation (SPK) is even remarkably 
superior to that of Type 1 diabetic uremic recipients undergoing living donor renal 
transplantation (LDRTx) alone, supporting the fact that freedom from diabetes has a clear 
survival advantage. Furthermore, if a suitable diabetic uremic patient is evaluated for 
transplantation, they would have historically been offered the choice between an SPK 
transplant or, if they had a suitable living donor, LDRTx followed by PAK. Since the 
uremic diabetic state is the actual starting point, the relevant waiting list survival to 
consider is actually that of a candidate that requires both a kidney and a pancreas: i.e., on 
the waitlist for an SPK, not the survival of a renal transplant recipient waiting for a 
pancreas alone as was used in the JAMA publication(3). If such a patient ultimately no 
longer required dialysis and were no longer diabetic, then there could be a greater patient 
survival advantage compared to remaining diabetic but free from renal failure. This study 
was designed to reproduce the original JAMA study from 2003 adding a waiting list 
comparison group (PAK transplanted group being compared to waitlisted SPK 
candidates), while also looking at kidney and pancreas allograft survival and extending 
the survival analyses to 10 years post-transplant. 
Methods: 
This study used data from the Organ Procurement and Transplantation Network 
(OPTN). The OPTN data system includes data on all donor, wait-listed candidates, and 
transplant recipients in the US, submitted by the members of the OPTN, and has been 
described elsewhere.  The Health Resources and Services Administration (HRSA), U.S. 
Department of Health and Human Services provides oversight to the activities of the 
OPTN contractor. The OPTN database was queried for candidates who were registered 
from January 1st, 1995 to December 31st, 2010 for an SPK transplant or a PAK 
transplant. The analysis excluded pediatric candidates (age < 18) and recipients who had 
a multi-organ transplant other than an SPK transplant or a previous transplant other than a 
kidney. Recipients who received a pancreas and a kidney at the same time from two 
different donors were also excluded from the analysis. After these exclusions, the cohort 
consisted of 25,361 patients. Of these patients 19,725 were waiting for an SPK and 
12,308 received an SPK. Additionally, 5,636 candidates were waiting for a PAK and 
3,358 received a PAK. PAK candidates were defined as receiving a kidney and waiting 
for a pancreas transplant. An additional cohort consisting of 736 deceased donor and 
1275 living donor kidney transplants in recipients with Type 1 diabetes mellitus 
performed during the same period were also included for comparison of kidney allograft 
survival. Pancreas allograft outcomes were determined from graft failures defined by 
individual centers as reported to UNOS. This analysis did not exclude PAK candidates 
with a creatinine greater than 2 ng/ml as was the case in the aforementioned study in 
JAMA (3)because creatinine was not a required field before October 1999. Therefore to 
reduce bias, it is necessary to include all candidates on the waiting list and transplanted 
before October 1999, regardless of creatinine values. Social security death master file 
(SSDMF) supplanted all death data. If transplanted recipients were not reported dead to 
the OPTN or not located in the SSDMF, then they were considered alive and were 
censored at 3,650 days. Candidates who were not transplanted were also censored at 
3,650 days plus median waiting time to transplant for the anticipated transplant type. The 
analysis compared outcomes for SPK waiting list candidates to SPK and PAK transplant 
recipients. Kaplan-Meier log-rank tests were used to test differences in unadjusted 
waitlist and post-transplant mortality. 
The analysis considered the impact of each transplant type: Deceased donor 
kidney alone, SPK, LDRTx alone, LDRTx followed by a pancreas and deceased donor 
kidney followed by a pancreas. The impact of each of these transplant types on pancreas 
and kidney allograft survival and patient survival was assessed. To accurately measure 
kidney allograft survival, candidates who are waiting for or received a PAK were 
subdivided into 4 groups by kidney donor type: Deceased donor kidney with or without a 
pancreas and LDRTx with or without a pancreas. A cox-proportional hazards model was 
used to determine if receiving a pancreas after a living or a deceased donor transplant 
impacted kidney allograft survival, while a log-rank test was used to determine if 
receiving a LDRTx increased graft survival of the pancreas compared to receiving a 
deceased donor kidney. A time dependent covariate analysis using cox-proportional 
hazard model was used to determine survival from listing for each transplant type. The 
models also allowed piecewise testing of mortality outcomes during 5 specific clinical 
time periods (0 to 90 days, 91 to 365 days, 1 to 3 years, 3 to 5 years, 5 to 10 years). The 
modeling followed the transplanted group until death or 10 years post-transplant. Hazard 
ratios were calculated to compare the risk of mortality within each time period, by 
comparing the average mortality for waitlisted candidates to the average mortality for 
transplanted recipients. SPK and PAK analyses were adjusted for year of listing and the 
PAK analysis for kidney donor type (living or deceased). Statistical analyses were 
performed using SAS version 9.3 (SAS Institute Inc. Cary, NC) and R 3.3.2. 
 
Results: 
Demographic distributions for SPK and PAK waitlisted candidate groups were 
clinically similar. However, because of the large number of subjects, it is not surprising 
there were statistical differences in the demographics within each group. Table 1 shows 
the patient demographics for each group. The median age at listing was 40 for SPK 
candidates and 42 for PAK candidates. For both groups, most candidates were male and 
Caucasian. The median time to transplant was 430 days for SPKs and 465 days for PAKs. 
The median interval from kidney to pancreas transplantation was 657 days and the 
median time from kidney transplantation until official listing for pancreas transplantation 
was 297 days. 
Waitlist and post-transplant patient survival by transplant procedure type are 
shown in Figure 1. The 10 year waitlist survival for the SPK waitlist group was 
dramatically lower than either of the transplanted groups (PAK or SPK). At 10 years, the 
survival for waitlisted SPK candidates was 26.4%. Post-transplant survival was very 
similar through 5 years for both groups (82.9% PAK and 86.4% SPK) but diverges 
thereafter, and at 10 years post-transplant SPK recipients had higher survival than PAK 
recipients (p < 0.001, PAK 63.2 % and SPK 70.3%).  
Kidney and pancreas graft survival for both PAK and SPK transplant types are 
shown in Figure 2. The cox-proportional hazard model comparing kidney donor type 
(living vs. deceased) and whether PAK candidates received a pancreas shows that 
receiving a LDRTx was associated with improved kidney graft survival compared to 
receiving a DDRTx (p < 0.001).  Furthermore, receiving a subsequent pancreas was also 
associated with improved long-term kidney graft survival (p < 0.001) versus not 
receiving a subsequent pancreas transplant, regardless of whether the kidney was from a 
deceased or living donor. However, the interaction between donor type and pancreas 
transplantation was not significant with respect to kidney graft survival (p = 0.09). 
In those patients who received a subsequent pancreas transplant, kidney graft 
survival was superior than those who did not. For example, ten-year kidney graft survival 
was 69.8% for recipients who received a LDRTx and a pancreas compared to 61.0% for 
those who only received a LDRTx. Similarly, 10-year kidney graft survival for recipients 
who received a deceased donor kidney transplant followed by a pancreas was 66.0%, 
while kidney graft survival for recipients who just received a deceased donor kidney was 
50.4%. The kidney graft survival in SPK recipients was 61% at 10 years. The best short-
term and long-term kidney graft survival was seen in patients receiving a LDRTx 
followed by a PAK transplant. In both cases of PAK transplants, regardless of the type of 
kidney allografts, kidney graft survival was superior to that of SPK transplants (69.8% 
and 66.0% vs. 61%, p <0.001).   
A Cox proportional hazard model was used to determine if receiving a LDRTx 
was associated with increased pancreas graft survival compared to recipients of DDRTx. 
At 10 years, PAK recipients who received a LDRTx had a pancreas graft survival of 
44.4% compared to 41.7% for those PAK recipients who received a deceased donor 
kidney (p < 0. 001). In comparison, SPK pancreas graft survival was 58.7% at 10 years.  
As both PAK and SPK transplants are potential, yet alternative definitive 
treatments for the same patient population, namely diabetic uremic patients, we sought to 
compare patient survival of these two transplant types to wait-listed diabetic uremic 
candidates.  Figure 3 shows the hazard ratios for patient survival of SPK and PAK 
transplant types relative to diabetic uremic patients remaining on the SPK waiting list. 
Panel one compares SPK recipients to waitlisted (WL) SPK candidates who did not 
receive a transplant (WL SPK No TX). The second panel compares PAK recipients to 
waitlisted SPK candidates who did not receive a transplant (WL SPK No TX). This 
comparison is particularly important because it shows the benefit of receiving a PAK 
compared to candidates who receive neither a kidney nor a pancreas. 
In the SPK analysis, survival at 90 days demonstrated no benefit of transplant 
compared to staying on the waitlist (HR =1.12, CI = [0.996, 1.25]), which is the case for 
almost all transplants where in many cases transplantation is even associated with a 
higher short-term mortality risk. However, beyond the first 90 days, there was highly 
significant patient survival benefit associated with receiving an SPK transplant that 
included time intervals from 90 to 365 days (HR =0.29, CI = [0.25, 0.33]), 1 to 3 years 
(HR =0.17, CI = [0.15, 0.18]), 3 to 5 years (HR =0.19, CI = [0.17, 0.21]), and which even 
extended out to 5 to 10 years (HR =0.24, CI = [0.21, 0.28]). Among the 7,417 SPK 
candidates who did not get a transplant 2,881 died (38.8%); this compared to 12,308 SPK 
recipients of whom 3,049 died over 10 years (24.8%). When comparing PAK recipients 
to SPK waitlisted candidates who did not receive a transplant there was also a strong 
patient survival benefit associated with PAK transplant at each time interval. Specifically, 
at all time points post-transplant, including up to 90 days (HR= 0.58, CI =[0.45-0.73]), up 
to one year (90 to 365 days) (HR = 0.22, CI = [0.17-0.27]), from 1 to 3 years (HR= 0.18, 
CI =[0.15-0.20]), from 3 to 5 years (HR= 0.28, CI =[0.23-0.32]) and from 5 to 10 year 
(HR= 0.34, CI=[0.28-0.41]) there was an observed benefit associated with PAK 
transplantation. A total of 953 recipients died after PAK transplants out of 3,358 
transplants at 10 years (28.4%) compared to 2,881 SPK candidates out of 7,417 SPK 
candidates (38.8%) who were waiting for a transplant.  Thus, when compared to an SPK 
waiting list uremic diabetic population, both SPK and PAK have a similar patient 
survival benefit (Figure 3). 
When evaluating the potential benefits of patient survival in PAK transplants, one 
can alternatively compare post-PAK survival to that of those who received a kidney and 
are waiting for a pancreas. Doing the analysis in this manner resulted in an estimated  
hazard of death after surgery in the first 90 days 3.1 times greater than staying on the 
waitlist(CI [2.3-4.0])(data not shown). Although the hazard ratio for the first 90 days 
demonstrates that there is an increased risk associated with transplantation, it is important 
to note that there were only 13 deaths within 90 days of PAK transplant out of 3,358 
PAK transplants. From 90 to 365 days the HR was 1.19 (CI [0.92-1.53]), and from 1 to 3 
years the HR fell to 1.0 (CI [0.81-1.23]). Longer term, the HR for death from 3 to 5 years 
was 1.17 (CI [0.93-1.45]), and from 5 to 10 years the HR was 1.07 (CI [0.84-1.37]). 
Overall 314 died out of 2,278 while waiting for a pancreas after receiving a kidney 
transplant (13.7%), compared 953 who died out of the 3,358 post-transplant recipients for 
PAKs (28.4%). 
In summary, PAK transplant recipients who receive both organs have an increased 
survival advantage compared to uremic candidates who receive neither a pancreas nor a 
kidney transplant (Figure 3, 2nd panel). Except for the first 90 days post-PAK, PAK 
recipients experienced similar patient mortality risk to recipients of kidneys who were 
waiting for a pancreas transplant.  Moreover, compared to uremic diabetic waitlisted 
patients, SPK and PAK recipients showed similar overall patient survival benefits (Figure 
3, 1st panel versus 2nd panel). 
Discussion 
For the Type 1 diabetic uremic transplant candidate, LDRTx followed by PAK 
transplantation is a very appealing alternative to the more commonly performed SPK 
transplantation (7-12). The primary advantages of a PAK compared to an SPK stem from 
the fact that a LDRTx is widely recognized to have superior patient and allograft survival 
outcomes compared to deceased donor renal transplantation. According to the Scientific 
Registry of Transplant Recipients and Organ Procurement and Transplantation Network 
(SRTR/OPTN) 2016 Annual Report, 6 months and 10 year graft survival rates for an 
LDRTx are significantly better than those of a standard criteria deceased donor kidney 
transplant, which is how the renal allograft would likely be classified in the SPK 
recipient(13).  The timing of an LDRTx also supports preemptive renal transplantation 
prior to the initiation of dialysis, which avoids the potential morbidity and cost of dialysis 
and may also be associated with an allograft and patient survival advantage (14-17). 
Moreover, due to choice of the local DSA to allocate two kidneys to two separate kidney 
recipients when an SPK is not placed locally, there are many isolated pancreas grafts that 
go untransplanted and are readily available for pancreas transplantation without a kidney. 
Increased use of these isolated pancreas allografts could result in a significantly reduced 
waiting time and potentially decreased mortality for the non-sensitized recipient 
interested in pursuing living donor renal transplantation followed by PAK(4). Finally, if 
LDRTx followed by PAK were aggressively pursued by most pancreas transplant centers, 
there would be a significant number of additional standard criteria donor renal allografts 
available for the deceased donor pool.  
There are two major disadvantages to PAK transplantation: the requirement for 
two separate operations and the separate origin of the renal and pancreatic allografts. In 
terms of the operations, the concern regarding undergoing two separate operations and 
courses of anesthesia has not been associated with any increased mortality as patient 
survival rates and  1 year technical graft failure rates are nearly identical for both SPK 
and PAK according to the IPTR database (96% patient survival rates and <10% technical 
graft failure rates for both)(18). Nonetheless, the PAK operation, by itself, is a 
significantly more straightforward and shorter operation than an SPK and the recipient is 
not uremic at the time of transplant. Also, the patients cardiac status has essentially 
undergone a pre-PAK stress test by virtue of the kidney transplant operation and 
therefore there is increased assurance of being fit cardiovascularly. It is also possible that 
the recipient may achieve an immunological advantage because they are already on 
baseline immunosuppression prior to pancreas transplantation in the PAK group(19).  
 Historically, PAK transplants have been associated with inferior pancreas 
allograft survival compared to SPK transplants (in reports from 2003-2004, 78% vs. 85% 
1-year graft survival, p≤ 0.0001)(20, 21) which was attributed to increased 
immunological pancreas graft loss in PAK recipients (in reports from 2003-2004, 5.2% 
vs. 1.8% at 1-year, p≤ 0.0001)(20, 21). In fact, this was true in our study as well, as it 
also included data from this early period. The separate donor origins of the pancreas and 
the kidney in the PAK recipients may account for some of these findings. Historically, 
following an SPK transplant, episodes of acute cellular rejection are more often detected 
and treated early because the recipients will manifest rejection of the transplanted kidney 
with a rise in serum creatinine, and the renal allograft is easily amenable to percutaneous 
biopsy whereas the pancreas was considered unsafe and difficult to biopsy. If the organs 
are from different donors, as is the case for PAK transplants, they may reject 
independently. One can conclude from this that if rejection is a frequent event and leads 
to graft loss, there would be an advantage to transplanting the kidney and the pancreas 
from the same donor, however the difference in immunological graft loss rates at 1 year 
between the two transplant types do not account for the entire difference in graft survival 
outcomes.  Additionally, it is important to note, that although immunologic graft loss is 
more common in PAK (1 year – 5.5%) compared to SPK (1 year – 2%), this rate has been 
improving with time for PAK (1 year immunological graft loss rates in 1994 were 28% 
for PAK and 4.87% for SPK) (18). During the last decade, there have been a number of 
publications describing advances in immunosuppression management following pancreas 
transplantation. The current direction of the field is induction with T-cell depleting 
antibody with steroid withdrawal (22-31).  The depleting antibodies used include rabbit 
anti-thymocyte globulin (22, 24, 25, 28, 29, 32) or alemtuzumab (anti-CD 52) (23, 26, 27, 
31). One of these studies was also calcineurin inhibitor free using alemtuzumab and 
MMF as maintenance immunosuppression (26), and another used alemtuzumab induction 
with monotherapy tacrolimus maintenance (31).  Of note, all of these studies 
demonstrated better pancreas allograft survival than that predicted by the International 
Pancreas Transplant Registry (IPTR) (21). In addition, of the 365 patients described in all 
of these studies, there were only 5 immunologic grafts losses (1.3%), which is again 
better than expected according to the IPTR (21). Of the two studies that permit 
comparison between PAK and SPK pancreas allograft survival rates, the PAK group 
fared better in both cases (91% vs 81% and 100% vs 90% respectively) (26, 31). These 
data suggest that we have entered a new era of immunosuppression where immunological 
graft loss is an infrequent occurrence. These data are further supported by more recent 
IPTR reports using T-cell depleting antibody induction protocols, particularly in the 
context of maintenance immunosuppression protocols that include sirolimus where the 1 
year pancreas graft survival rates have improved compared to the entire pancreas 
transplant recipient population from 80% to 89.3% for PAK and from 85.5% to 89.6% 
for SPK(18).  
PAK and SPK transplants result in similar patient survival, and both outcomes are 
superior to patient survival of kidney transplantation alone. We were somewhat surprised 
by the splaying of the patient survival curves beyond 4 years comparing SPK to PAK, but 
we also must acknowledge that in looking at 10 year survival, this may be misleading. It 
is likely that the increased incidence of pancreas allograft failure was a major contributor 
to this finding and, as discussed previously, this has improved significantly during the 
study period. In fact, it would be very interesting to reevaluate these data in another 10 
years’ time or focusing in on specific immunosuppression regimens. Ultimately, 
achieving freedom from dialysis and insulin independence should be the goal for all 
eligible type 1 diabetic uremic patients seeking transplantation therapy, as this provides 
the optimal patient survival benefit.(6) If achieving freedom from dialysis and insulin 
independence is the ultimate goal, patients should be offered either: 1) living donor 
kidney followed by pancreas transplantation if medically suitable and no 
contraindications have developed in the interim, or 2) SPK transplantation, if no living 
donor is available, the patient desires one operation or the expected waiting time is short. 
Both options provide excellent kidney graft survival and the possibility of potential 
preemptive kidney transplantation, and freedom from diabetes. In centers and regions 
where the waiting times for an SPK can be quite long, a PAK transplant can afford a 
patient a much shorter period on the waiting list (patient survival beyond one year on the 
SPK waiting list deteriorates rapidly). Elimination of dialysis and insulin requirements 
should be the dual goals for all medically suitable patients with uremic type-1 diabetes, 
whether this is achieved with a PAK or SPK. 
The present study extends beyond the original JAMA publication by extending 
the follow-up from 4 to 10 years and uniquely looking at a new comparison for the PAK 
group (PAKs vs WL SPK candidates). Based on these data, not performing a PAK 
transplant represents  a missed opportunity. The decline in PAK transplantation is a 
leading contributor to the decreased volume trend in pancreas transplantation overall and 
reversing this trend represents an important opportunity for increasing the number of 
pancreas transplants. 
A general limitation of the analysis is picking an appropriate comparison group 
for transplanted PAK recipients. There can be several different comparison groups such 
as kidney alone transplants with diabetes and no intent to get a pancreas, waitlisted SPK 
candidates, or candidates who received a kidney and are waiting for a pancreas. The 
analyses here expand on previous analyses by including the latter two of the three 
comparison groups mentioned above. In the last of these comparison groups, only those 
who are healthy enough to get a PAK are included in the PAK transplanted group, which 
could potentially bias the results because it does not include the patients that experienced 
kidney graft loss before the pancreas transplant. However, the same is true of the 
comparison group of prior kidney transplant recipients who are eligible for a PAK. 
Nonetheless, this analysis is retrospective.  With these limitations in mind, the results 
support the notion that PAK transplants are an appropriate option for some diabetic 
uremic candidates who have a suitable living donor and are expected to have a long wait 
time for an SPK transplant, thereby achieving rapid reversal of uremia and reducing 
excess mortality. Receiving a subsequent pancreas after  kidney transplant is associated 
with increased kidney graft survival and no increase in long-term  mortality for PAK 
recipients. 
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Table 1: Demographic Information by Expected Transplant Procedure Type. Variable PAK N=5636 SKP N=19725 P overall GENDER:   0.016     Female 2403 (42.6%) 8053 (40.8%)      Male 3233 (57.4%) 11672 (59.2%)  Ethnicity:   <0.001     White 4728 (83.9%) 14629 (74.2%)      Black 480 (8.52%) 2956 (15.0%)      Hispanic 339 (6.01%) 1681 (8.52%)      Asian 43 (0.76%) 229 (1.16%)      Other 46 (0.82%) 230 (1.17%)  Listing Age 41.8 (8.10) 40.2 (8.42) <0.001 ABO:   <0.001     A 2265 (40.2%) 7145 (36.2%)      AB 220 (3.90%) 721 (3.66%)      B 645 (11.4%) 2383 (12.1%)      O 2506 (44.5%) 9476 (48.0%)  BMI:  25.2 (4.24)   24.9 (4.25) <0.001 Transplanted:   <0.001     No 2278 (40.4%) 7417 (37.6%)      Yes 3358 (59.6%) 12308 (62.4%)  Allocation PRA   <0.001 0 1785 (67.6%) 6383 (76.0%)  1-19 518 (19.6%) 1206 (14.4%)  20-79 251 (9.50%) 597 (7.11%)  80+ 87 (3.29%) 209 (2.49%)  HLA Mismatch   <0.001     0 49 (1.47%) 215 (1.77%)      1 104 (3.13%) 157 (1.29%)      2 277 (8.33%)  412 (3.40%)      3 632 (19.0%) 1599 (13.2%)        4 866 (26.1%) 3187 (26.3%)      5 918 (27.6%)  4129 (34.0%)      6 478 (14.4%)   2433 (20.1%)  
 
 Figure legends: 
Figure 1: SPK Waitlist survival and post-transplant survival for PAK and SPK 
post-transplant recipients. 
Figure 2A: Kidney graft survival for SPK and PAK candidate groups. Groups are: 
1) Type 1 DM deceased donor kidney transplant alone (Deceased KI-No PA), 2) 
Deceased donor kidney transplant followed by pancreas after kidney transplant 
(Deceased KI-PA TX), 3) Type 1 DM live donor kidney transplant alone (Living KI-
No PA), 4) Live donor kidney transplant followed by pancreas after kidney 
transplant (Living KI-PA TX) and 5) Simultaneous pancreas-kidney transplant 
(SPK-KI). 
 
Figure 2B: Pancreas graft survival for SPK and PAK candidate groups. Groups 
are: 1) Deceased donor kidney transplant followed by pancreas after kidney 
transplant (Deceased donor KI-PAK), 2) Live donor kidney transplant followed by 
pancreas after kidney transplant (Living donor KI-PAK), 3) Simultaneous 
pancreas-kidney transplant (SPK-PA). 
 
Figure 3: Patient Survival from Transplant 
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Figure 2A: Kidney graft survival for SPK and PAK candidate groups. Groups are: 
1) Type 1 DM deceased donor kidney transplant alone (Deceased KI-No PA), 2) 
Deceased donor kidney transplant followed by pancreas after kidney transplant 
(Deceased KI-PA TX), 3) Type 1 DM live donor kidney transplant alone (Living KI-
No PA), 4) Live donor kidney transplant followed by pancreas after kidney 
transplant (Living KI-PA TX) and 5) Simultaneous pancreas-kidney transplant 
(SPK-KI). 
 
 
 
Figure 2B: Pancreas graft survival for SPK and PAK candidate groups. Groups 
are: 1) Deceased donor kidney transplant followed by pancreas after kidney 
transplant (Deceased donor KI-PAK), 2) Live donor kidney transplant followed by 
pancreas after kidney transplant (Living donor KI-PAK), 3) Simultaneous 
pancreas-kidney transplant (SPK-PA). 
 
 
 
 
 
Figure 3: Patient Survival from Transplant 
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